Who Supplies Verapamil to India from BANGLADESH

Importing finished pharmaceutical formulations containing Verapamil into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before registration and import. Applications for registration and import should be submitted to the Drugs Controller General (I) at CDSCO. The registration process involves submitting Form 40 or 41, along with the required documentation, and may take several months, depending on the completeness of the application and the nature of the drug. Specific requirements for Verapamil formulations under HS Code 30049072 include detailed product information, manufacturing details, and compliance with Indian pharmacopoeia standards.

Imported Verapamil formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, is required to demonstrate the product's shelf-life under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported drugs. Failure to meet these standards can result in rejection of the batch and potential penalties.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Bangladesh have facilitated smoother trade, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for Bangladeshi manufacturers.

India imports finished Verapamil formulations to meet the demand for specific dosage forms and branded products not available domestically. The market size for Verapamil in India is substantial, driven by its use in treating cardiovascular conditions. Domestic manufacturers may lack the capacity to produce certain formulations, leading to reliance on imports to fulfill market needs.

The Basic Customs Duty (BCD) for Verapamil formulations under HS Code 30049072 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the CIF value. Additionally, a Social Welfare Surcharge (SWS) of 10% on BCD is levied. This results in a total landed duty of approximately 23.536% of the CIF value. There are no specific exemptions or concessional rates for imports from Bangladesh under this HS code.

India sources Verapamil formulations from Bangladesh due to competitive advantages such as cost-effective manufacturing and compliance with international quality standards. Bangladesh's share in India's Verapamil import market is significant, offering specialized formulations and dosage forms that may not be produced domestically. Other suppliers include China, Germany, and the United States, but Bangladesh's proximity and trade agreements enhance its competitive position.

India imports Verapamil formulations from Bangladesh due to the availability of specialized dosage forms and branded products not produced domestically. Bangladesh's compliance with international quality standards and cost-effective manufacturing processes make it an attractive source for these formulations.

Compared to other origins like China, the European Union, and the United States, Bangladesh offers competitive pricing and quality. Its proximity to India and established trade agreements further enhance its appeal as a sourcing destination.

Potential risks include reliance on a single source, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. While no significant shortages have been reported, importers should monitor these factors to mitigate potential impacts.

1. 1Dual Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs to optimize procurement costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with quality standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with CDSCO using Form 40 or 41.
3. 3Drug Import License: Secure a license for importing drugs.
4. 4No Objection Certificate (NOC): Obtain NOC from the Ministry of Health and Family Welfare.
5. 5Customs Broker: Engage a licensed customs broker for clearance.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049072 to confirm classification and duty rates.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating GMP compliance.
3. 3Good Manufacturing Practice (GMP) Certificate: From the manufacturing facility.
4. 4Drug Master File (DMF): Providing detailed manufacturing information.
5. 5Stability Data